LATEST NEWS

Nyxoah Raises €15 Million in New Financing, Completes BLAST OSA Clinical Study

Nyxoah S.A., a medical device company focused on the development and commercialization of a best-in-class hypoglossal nerve stimulation (HGNS) therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it successfully raised an additional €15 million ($17.1 million USD) in their most recent round of equity financing.

The financing was led by Cochlear Limited (https://www.cochlear.com), an Australian medical device company (ASX: COH) and global leader in implantable hearing solutions. Cochlear invested €13 million and the round was completed by several existing Nyxoah shareholders. A representative of Cochlear has joined the Nyxoah Board.

Robert Taub, Chairman of the Nyxoah Board said: “We are extremely pleased to welcome Cochlear as a new investor. Their board-level participation will accelerate Nyxoah’s vision of becoming a leader in OSA therapy.”

Jan Janssen, Chief Technology Officer of Cochlear said: “Cochlear actively monitors the market for novel technologies and implantable devices that over the long term may leverage its core business. Nyxoah’s minimally invasive solution presents an attractive alternative for patients with compliance or intolerance issues in respect of existing therapies. We look forward to working with Nyxoah.”

Nyxoah recently completed the BLAST-OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) clinical study, an essential milestone for its CE marking dossier already submitted to the European regulatory body.

“Patients from the BLAST OSA study show a major improvement in sleep apnea symptoms including a significant reduction of ODI (Oxygen Desaturation Index) and AHI (Apnea Hypopnea Index),” said Enrique Vega, Chief Executive Officer of Nyxoah S.A. “The Nyxoah therapy was also associated with high patient compliance and improvements in patient Quality of Life. We look forward to publishing the clinical results in a leading medical journal during 2019.”

The additional financing will be used to initiate post-CE Mark European market development activities and to work toward Investigational Device Exemption (IDE) with the US Food and Drug Administration (FDA).

Lihi

Recent Posts

RIKEN adopts Siemens’ emulation and High-Level Synthesis platforms for next-generation AI device research

Siemens’ emulation and HLS platforms support leading Japanese research institute’s evaluation of optimized AI computing…

5 hours ago

Nilus Raises $10M, Reaching $18M in Funding to Lead the Future of AI-Powered Treasury Management

Nilus, the first proactive AI-powered treasury management platform, has raised an additional $10M in a…

6 hours ago

Reeco Raises $15M Series A Round to Modernize Hotel Procurement with AI-Driven Procure-to-Pay Platform

Funding will drive Reeco’s strategic growth initiatives as it streamlines back-of-house operations for North American…

3 days ago

Introducing RUBY-W2: u-blox’s first Wi-Fi 7 module for superior Apple® CarPlay and Android® Auto user experience

Connect more concurrent users with the advanced Wi-Fi 7 capabilities of the Snapdragon® Auto Connectivity…

3 days ago

Anritsu Extend Spectrum Measurement Frequency to Millimeter-wave Band with External Mixer from VDI or Eravant

- Supporting Millimeter-wave Band of Medical and Automotive Device Evaluations - Anritsu Corporation is pleased…

3 days ago

ROHM Offers the Industry’s Smallest* Terahertz Wave Oscillation and Detection Devices

Price range is less than one-tenth that of conventional devices while achieving remarkable space-savings ROHM…

3 days ago